We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

HUTCHMED

On the right track

Outlook | 01 September 2022

Futura Medical

FM71 achieves all primary and secondary endpoints

Lighthouse | 31 August 2022

Arecor Therapeutics

Acquisition of Tetris Pharma and £6m equity raise

Lighthouse | 01 August 2022

ANGLE

£20m raise funds commercialisation through to mid-2024

Lighthouse | 15 July 2022

Allergy Therapeutics

Key data on track, return to growth expected next year

Lighthouse | 15 July 2022

Avacta

AVA6000 set for third dose escalation stage

Lighthouse | 30 June 2022

Redx Pharma

All the ingredients for success now in place

Update | 29 June 2022

Redx Pharma

Jazz Pharmaceuticals $5m milestone triggered

Lighthouse | 15 June 2022

Scancell

First Moditope oncology vaccine enters the clinic

Lighthouse | 13 June 2022

Redx Pharma

£34.3m raise extends runway through key data points

Lighthouse | 07 June 2022
1 2 3 4 5 6 7 8 9 10 >
366 results found.